{"transactions":[{"id":758690,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-29T20:37:18.000Z","date":"2026-05-28","kind":"gift","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents gifts to adult sons who do not share same household with reporting person."}],"balance_after":2173307,"source":{"system":"sec-edgar","filing":"0000897069-26-001285","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706926001285/form4.xml","form_type":"4"}},{"id":901506,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":20016,"kind":"person","name":"Tendler Craig","position":1,"cik":"0002061924","reported_name":"Tendler Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2026-02-17T21:21:30.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":156240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."}],"balance_after":156240,"derivative":{"exercise_price":1.29,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":156240},"source":{"system":"sec-edgar","filing":"0000897069-26-000369","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2061924/000089706926000369/form4.xml","form_type":"4"}},{"id":900978,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2026-02-17T21:19:47.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":156240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."}],"balance_after":156240,"derivative":{"exercise_price":1.29,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":156240},"source":{"system":"sec-edgar","filing":"0000897069-26-000367","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706926000367/form4.xml","form_type":"4"}},{"id":900961,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":51611,"kind":"person","name":"MANUSO JAMES S J","position":1,"cik":"0001236365","reported_name":"MANUSO JAMES S J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2026-02-17T21:17:30.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":156240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."}],"balance_after":156240,"derivative":{"exercise_price":1.29,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":156240},"source":{"system":"sec-edgar","filing":"0000897069-26-000365","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706926000365/form4.xml","form_type":"4"}},{"id":900959,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":66198,"kind":"person","name":"List Alan","position":1,"cik":"0001858530","reported_name":"List Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2026-02-17T21:16:01.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":156240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."}],"balance_after":156240,"derivative":{"exercise_price":1.29,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":156240},"source":{"system":"sec-edgar","filing":"0000897069-26-000363","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706926000363/form4.xml","form_type":"4"}},{"id":901608,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2026-02-17T21:09:41.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":156240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026."}],"balance_after":156240,"derivative":{"exercise_price":1.29,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":156240},"source":{"system":"sec-edgar","filing":"0000897069-26-000360","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000089706926000360/form4.xml","form_type":"4"}},{"id":943189,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2026-01-08T21:35:21.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":273696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025."}],"balance_after":273696,"derivative":{"exercise_price":0.73,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":273696},"source":{"system":"sec-edgar","filing":"0000897069-26-000112","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706926000112/form4.xml","form_type":"4"}},{"id":943186,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2026-01-08T21:33:52.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":610332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025."}],"balance_after":610332,"derivative":{"exercise_price":0.73,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":610332},"source":{"system":"sec-edgar","filing":"0000897069-26-000111","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706926000111/form4.xml","form_type":"4"}},{"id":964969,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2025-12-17T11:37:42.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":1531367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025."}],"balance_after":1531367,"derivative":{"exercise_price":1.02,"expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":1531367},"source":{"system":"sec-edgar","filing":"0000897069-25-001809","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706925001809/form4.xml","form_type":"4"}},{"id":964968,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2025-12-17T11:36:45.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":3414891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025."}],"balance_after":3414891,"derivative":{"exercise_price":1.02,"expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":3414891},"source":{"system":"sec-edgar","filing":"0000897069-25-001807","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706925001807/form4.xml","form_type":"4"}},{"id":1197427,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":20016,"kind":"person","name":"Tendler Craig","position":1,"cik":"0002061924","reported_name":"Tendler Craig","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2025-03-19T23:13:50.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":151883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of March 10, 2025."}],"balance_after":151883,"derivative":{"exercise_price":1.88,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":151883},"source":{"system":"sec-edgar","filing":"0000897069-25-000664","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2061924/000089706925000664/form4.xml","form_type":"4"}},{"id":1311370,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2025-01-06T22:08:15.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":51275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."}],"balance_after":51275,"derivative":{"exercise_price":4.11,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":51275},"source":{"system":"sec-edgar","filing":"0000897069-25-000037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000089706925000037/form4.xml","form_type":"4"}},{"id":1310553,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":51611,"kind":"person","name":"MANUSO JAMES S J","position":1,"cik":"0001236365","reported_name":"MANUSO JAMES S J","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2025-01-06T21:58:18.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":59590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."}],"balance_after":59590,"derivative":{"exercise_price":4.11,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":59590},"source":{"system":"sec-edgar","filing":"0000897069-25-000035","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706925000035/form4.xml","form_type":"4"}},{"id":1310552,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":66198,"kind":"person","name":"List Alan","position":1,"cik":"0001858530","reported_name":"List Alan","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2025-01-06T21:56:27.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":51275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."}],"balance_after":51275,"derivative":{"exercise_price":4.11,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":51275},"source":{"system":"sec-edgar","filing":"0000897069-25-000033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706925000033/form4.xml","form_type":"4"}},{"id":1310637,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2025-01-06T21:54:16.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":51275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program.  One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025."}],"balance_after":51275,"derivative":{"exercise_price":4.11,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":51275},"source":{"system":"sec-edgar","filing":"0000897069-25-000031","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706925000031/form4.xml","form_type":"4"}},{"id":1365081,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-11-14T21:48:55.000Z","date":"2024-11-12","kind":"grant","planned":false,"acquired":true,"shares":1065990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of November 12, 2024."}],"balance_after":1065990,"derivative":{"exercise_price":4.94,"expiration_date":"2034-11-12","underlying":"Common Stock","underlying_shares":1065990},"source":{"system":"sec-edgar","filing":"0000897069-24-002166","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924002166/form4.xml","form_type":"4"}},{"id":1365080,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-11-14T21:46:15.000Z","date":"2024-11-12","kind":"grant","planned":false,"acquired":true,"shares":489848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of November 12, 2024."}],"balance_after":489848,"derivative":{"exercise_price":4.94,"expiration_date":"2034-11-12","underlying":"Common Stock","underlying_shares":489848},"source":{"system":"sec-edgar","filing":"0000897069-24-002164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924002164/form4.xml","form_type":"4"}},{"id":1382913,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:47:13.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":4.14,"exercise_date":"2024-10-18","expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924002011/form4.xml","form_type":"4"}},{"id":1382912,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:47:13.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":3.69,"exercise_date":"2024-10-18","expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924002011/form4.xml","form_type":"4"}},{"id":1382911,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":24591,"kind":"person","name":"Ng George K","position":1,"cik":"0001638744","reported_name":"Ng George K","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:47:13.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":35780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":35780,"derivative":{"exercise_price":2.24,"exercise_date":"2024-10-18","expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":35780},"source":{"system":"sec-edgar","filing":"0000897069-24-002011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1638744/000089706924002011/form4.xml","form_type":"4"}},{"id":1382905,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":66198,"kind":"person","name":"List Alan","position":1,"cik":"0001858530","reported_name":"List Alan","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:41:46.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":4.14,"exercise_date":"2024-10-18","expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002007","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924002007/form4.xml","form_type":"4"}},{"id":1382904,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":66198,"kind":"person","name":"List Alan","position":1,"cik":"0001858530","reported_name":"List Alan","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:41:46.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":3.69,"exercise_date":"2024-10-18","expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002007","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924002007/form4.xml","form_type":"4"}},{"id":1382903,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":51611,"kind":"person","name":"MANUSO JAMES S J","position":1,"cik":"0001236365","reported_name":"MANUSO JAMES S J","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:36:17.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":4.14,"exercise_date":"2024-10-18","expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002003","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924002003/form4.xml","form_type":"4"}},{"id":1382902,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":51611,"kind":"person","name":"MANUSO JAMES S J","position":1,"cik":"0001236365","reported_name":"MANUSO JAMES S J","relationship":{"director":true}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:36:17.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":13553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":13553,"derivative":{"exercise_price":3.69,"exercise_date":"2024-10-18","expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":13553},"source":{"system":"sec-edgar","filing":"0000897069-24-002003","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924002003/form4.xml","form_type":"4"}},{"id":1382901,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:10:14.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":191280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the stock options become exercisable on the first, second and third anniversary of February 28, 2024."}],"balance_after":191280,"derivative":{"exercise_price":4.14,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":191280},"source":{"system":"sec-edgar","filing":"0000897069-24-001996","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001996/form4.xml","form_type":"4"}},{"id":1382900,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:10:14.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":71560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023."}],"balance_after":71560,"derivative":{"exercise_price":3.69,"expiration_date":"2033-04-07","underlying":"Common Stock","underlying_shares":71560},"source":{"system":"sec-edgar","filing":"0000897069-24-001996","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001996/form4.xml","form_type":"4"}},{"id":1382899,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:10:14.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":357800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":357800,"derivative":{"exercise_price":3.69,"exercise_date":"2024-10-18","expiration_date":"2031-07-01","underlying":"Common Stock","underlying_shares":357800},"source":{"system":"sec-edgar","filing":"0000897069-24-001996","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001996/form4.xml","form_type":"4"}},{"id":1382898,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":43159,"kind":"person","name":"Bianco James A.","position":1,"cik":"0001198554","reported_name":"Bianco James A.","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-23T00:10:14.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":2323307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":2323307,"source":{"system":"sec-edgar","filing":"0000897069-24-001996","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001996/form4.xml","form_type":"4"}},{"id":1382897,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:01:03.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":66658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of February 28, 2024."}],"balance_after":66658,"derivative":{"exercise_price":4.14,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":66658},"source":{"system":"sec-edgar","filing":"0000897069-24-001992","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001992/form4.xml","form_type":"4"}},{"id":1382896,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:01:03.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":15744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023."}],"balance_after":15744,"derivative":{"exercise_price":3.69,"expiration_date":"2033-04-07","underlying":"Common Stock","underlying_shares":15744},"source":{"system":"sec-edgar","filing":"0000897069-24-001992","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001992/form4.xml","form_type":"4"}},{"id":1382895,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:01:03.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":232570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of November 15, 2023."}],"balance_after":232570,"derivative":{"exercise_price":3.69,"expiration_date":"2032-11-15","underlying":"Common Stock","underlying_shares":232570},"source":{"system":"sec-edgar","filing":"0000897069-24-001992","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001992/form4.xml","form_type":"4"}},{"id":1382894,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:01:03.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":68438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":68438,"derivative":{"exercise_price":2.24,"exercise_date":"2024-10-18","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":68438},"source":{"system":"sec-edgar","filing":"0000897069-24-001992","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001992/form4.xml","form_type":"4"}},{"id":1382893,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":69764,"kind":"person","name":"Dearborn Dan","position":1,"cik":"0001975443","reported_name":"Dearborn Dan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-23T00:01:03.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":33991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""}],"balance_after":33991,"derivative":{"exercise_price":2.24,"exercise_date":"2024-10-18","expiration_date":"2026-01-17","underlying":"Common Stock","underlying_shares":33991},"source":{"system":"sec-edgar","filing":"0000897069-24-001992","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089706924001992/form4.xml","form_type":"4"}},{"id":1383086,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":86659,"kind":"person","name":"Yamashita Dennis","position":1,"cik":"0002039412","reported_name":"Yamashita Dennis","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Options (Right to Buy)","published_at":"2024-10-22T21:12:33.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":196790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the \"Merger Agreement\"), among the Issuer (fka \"Kintara Therapeutics, Inc.\"), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer (\"Merger Sub\"), and TuHURA Biosciences, Inc., a Delaware corporation (\"Private TuHURA\"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the \"Merger\") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to \"TuHURA Biosciences, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third of the stock options become exercisable on the first, second, and third anniversary of January 19, 2024."}],"balance_after":196790,"derivative":{"exercise_price":3.69,"expiration_date":"2034-01-19","underlying":"Common Stock","underlying_shares":196790},"source":{"system":"sec-edgar","filing":"0000897069-24-002015","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2039412/000089706924002015/form4.xml","form_type":"4"}},{"id":1790827,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2023-09-01T22:00:39.000Z","date":"2023-08-30","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023."}],"balance_after":8500,"derivative":{"exercise_price":4.655,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001493152-23-031538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315223031538/ownership.xml","form_type":"4"}},{"id":1790826,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":29284,"kind":"person","name":"FAVORITO TAMARA A","position":1,"cik":"0001288232","reported_name":"FAVORITO TAMARA A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2023-09-01T22:00:38.000Z","date":"2023-08-30","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023."}],"balance_after":8500,"derivative":{"exercise_price":4.655,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001493152-23-031535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315223031535/ownership.xml","form_type":"4"}},{"id":1791079,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Interim CFO"}}],"security":"Options (Right to Buy)","published_at":"2023-09-01T22:00:35.000Z","date":"2023-08-30","kind":"grant","planned":false,"acquired":true,"shares":23142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024."}],"balance_after":23142,"derivative":{"exercise_price":4.655,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":23142},"source":{"system":"sec-edgar","filing":"0001493152-23-031537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000149315223031537/ownership.xml","form_type":"4"}},{"id":1790825,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2023-09-01T22:00:32.000Z","date":"2023-08-30","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023."}],"balance_after":8500,"derivative":{"exercise_price":4.655,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001493152-23-031536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315223031536/ownership.xml","form_type":"4"}},{"id":1790824,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options (Right to Buy)","published_at":"2023-09-01T22:00:30.000Z","date":"2023-08-30","kind":"grant","planned":false,"acquired":true,"shares":10175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024."}],"balance_after":10175,"derivative":{"exercise_price":4.655,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":10175},"source":{"system":"sec-edgar","filing":"0001493152-23-031534","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315223031534/ownership.xml","form_type":"4"}},{"id":1870435,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and CFO"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-06-02T20:05:29.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":59800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 59,800 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in full on June 1, 2024."}],"balance_after":68902,"source":{"system":"sec-edgar","filing":"0001493152-23-019950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000149315223019950/ownership.xml","form_type":"4"}},{"id":2060394,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-01-07T00:26:18.000Z","date":"2023-01-05","kind":"other","acquired":true,"shares":363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,801 restricted stock units that are unvested."}],"balance_after":5302,"source":{"system":"sec-edgar","filing":"0001493152-23-000860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315223000860/ownership.xml","form_type":"4"}},{"id":2195765,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2022-08-03T20:30:45.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":720260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter."}],"balance_after":720260,"derivative":{"exercise_price":0.1757,"expiration_date":"2022-08-02","underlying":"Common Stock","underlying_shares":720260},"source":{"system":"sec-edgar","filing":"0001493152-22-021172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222021172/ownership.xml","form_type":"4"}},{"id":2195764,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-03T20:30:45.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":240087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023."}],"balance_after":277273,"source":{"system":"sec-edgar","filing":"0001493152-22-021172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222021172/ownership.xml","form_type":"4"}},{"id":2195760,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2022-08-03T20:30:38.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":720260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter."}],"balance_after":720260,"derivative":{"exercise_price":0.1757,"expiration_date":"2022-08-02","underlying":"Common Stock","underlying_shares":720260},"source":{"system":"sec-edgar","filing":"0001493152-22-021171","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222021171/ownership.xml","form_type":"4"}},{"id":2195759,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-03T20:30:38.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":240087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023."}],"balance_after":246905,"source":{"system":"sec-edgar","filing":"0001493152-22-021171","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222021171/ownership.xml","form_type":"4"}},{"id":2196093,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2022-08-03T20:30:30.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":1200634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter."}],"balance_after":1200634,"derivative":{"exercise_price":0.1757,"expiration_date":"2022-08-02","underlying":"Common Stock","underlying_shares":1200634},"source":{"system":"sec-edgar","filing":"0001493152-22-021170","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000149315222021170/ownership.xml","form_type":"4"}},{"id":2196092,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-03T20:30:30.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":400145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023."}],"balance_after":455145,"source":{"system":"sec-edgar","filing":"0001493152-22-021170","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000149315222021170/ownership.xml","form_type":"4"}},{"id":2214645,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2022-07-05T20:05:57.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022."}],"balance_after":100000,"derivative":{"exercise_price":0.255,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-22-018526","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222018526/ownership.xml","form_type":"4"}},{"id":2214644,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2022-07-05T20:05:52.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022."}],"balance_after":100000,"derivative":{"exercise_price":0.255,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-22-018527","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222018527/ownership.xml","form_type":"4"}},{"id":2214643,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":29284,"kind":"person","name":"FAVORITO TAMARA A","position":1,"cik":"0001288232","reported_name":"SEYMOUR TAMARA A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2022-07-05T20:05:43.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022."}],"balance_after":100000,"derivative":{"exercise_price":0.255,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-22-018529","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000149315222018529/ownership.xml","form_type":"4"}},{"id":2388958,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"Hoffman Robert E.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-17T21:00:46.000Z","date":"2022-02-15","kind":"purchase","acquired":true,"shares":55000,"price":0.469,"value":25795.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4625 to $0.4697 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0000905718-22-000393","document":"kintara_fm4feb152022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000090571822000393/kintara_fm4feb152022.xml","form_type":"4"}},{"id":2478919,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:09:59.000Z","date":"2021-12-08","kind":"purchase","acquired":true,"shares":28700,"price":0.677,"value":19429.9,"ownership":{"direct":true},"balance_after":37186,"source":{"system":"sec-edgar","filing":"0000899243-21-047520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321047520/doc4.xml","form_type":"4"}},{"id":2480636,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Strategic Partnerships"}}],"security":"Common Stock","published_at":"2021-12-08T21:09:27.000Z","date":"2021-12-07","kind":"purchase","acquired":true,"shares":38109,"price":0.6376,"value":24298.2984,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63115 to $0.6415 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":55500,"source":{"system":"sec-edgar","filing":"0000899243-21-047320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321047320/doc4.xml","form_type":"4"}},{"id":2480635,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Strategic Partnerships"}}],"security":"Common Stock","published_at":"2021-12-08T21:09:27.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":11891,"price":0.5902,"value":7018.0682,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.5902 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":17391,"source":{"system":"sec-edgar","filing":"0000899243-21-047320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321047320/doc4.xml","form_type":"4"}},{"id":2495219,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-24T21:06:41.000Z","date":"2021-11-22","kind":"purchase","acquired":true,"shares":3000,"price":0.7423,"value":2226.9,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-21-046043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321046043/doc4.xml","form_type":"4"}},{"id":2518136,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"HOFFMAN ROBERT","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options (Right to Buy)","published_at":"2021-11-10T21:18:07.000Z","date":"2021-11-08","kind":"grant","acquired":true,"shares":3519170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to the reporting person's continued employment, the shares subject to the option shall vest as follows: 25% of the shares subject to the option shall vest on November 8, 2022, and the remainder shall vest in equal monthly installments over the following thirty-six (36) months."}],"balance_after":3519170,"derivative":{"exercise_price":0.96,"expiration_date":"2031-11-08","underlying":"Common Stock","underlying_shares":3519170},"source":{"system":"sec-edgar","filing":"0000899243-21-043913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000089924321043913/doc4.xml","form_type":"4"}},{"id":2561970,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":68503,"kind":"person","name":"Murphy Keith","position":1,"cik":"0001536583","reported_name":"Murphy Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2021-09-23T00:43:25.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.24,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000905718-21-001227","document":"kintara_fm4sep222021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821001227/kintara_fm4sep222021.xml","form_type":"4"}},{"id":2561969,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2021-09-23T00:40:24.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.24,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000905718-21-001225","document":"kintara_fm4sep222021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821001225/kintara_fm4sep222021.xml","form_type":"4"}},{"id":2561968,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":29284,"kind":"person","name":"FAVORITO TAMARA A","position":1,"cik":"0001288232","reported_name":"SEYMOUR TAMARA A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2021-09-23T00:37:57.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021."}],"balance_after":35000,"derivative":{"exercise_price":1.24,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000905718-21-001223","document":"kintara_fm4sep222021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821001223/kintara_fm4sep222021.xml","form_type":"4"}},{"id":2562257,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"HOFFMAN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2021-09-23T00:35:13.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.24,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000905718-21-001221","document":"kintara_fm4sep222021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000090571821001221/kintara_fm4sep222021.xml","form_type":"4"}},{"id":2561963,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2021-09-23T00:31:21.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.24,"expiration_date":"2031-09-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000905718-21-001219","document":"kintara_fm4sep222021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821001219/kintara_fm4sep222021.xml","form_type":"4"}},{"id":2732981,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":29284,"kind":"person","name":"FAVORITO TAMARA A","position":1,"cik":"0001288232","reported_name":"SEYMOUR TAMARA A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Grant)","published_at":"2021-05-03T20:34:19.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, one-third of the options vest on April 29, 2022, with the remaining options vesting in eight equal quarterly installments commencing on July 29, 2022."}],"balance_after":75000,"derivative":{"exercise_price":1.37,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000905718-21-000652","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000652/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735832,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-04-29T20:06:28.000Z","date":"2021-04-29","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."}],"balance_after":0,"derivative":{"exercise_date":"2016-04-29","underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0000905718-21-000631","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000631/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735831,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-29T20:06:28.000Z","date":"2021-04-29","kind":"exercise","acquired":true,"shares":750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00."}],"balance_after":6818,"source":{"system":"sec-edgar","filing":"0000905718-21-000631","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000631/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735830,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-29T20:06:28.000Z","date":"2021-04-29","kind":"other","acquired":true,"shares":6,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock."}],"balance_after":6068,"source":{"system":"sec-edgar","filing":"0000905718-21-000631","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000631/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735835,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-04-29T20:06:02.000Z","date":"2021-04-29","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."}],"balance_after":0,"derivative":{"exercise_date":"2016-04-29","underlying":"Common Stock","underlying_shares":938},"source":{"system":"sec-edgar","filing":"0000905718-21-000630","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000630/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735834,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-29T20:06:02.000Z","date":"2021-04-29","kind":"exercise","acquired":true,"shares":938,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00."}],"balance_after":8486,"source":{"system":"sec-edgar","filing":"0000905718-21-000630","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000630/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735833,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-29T20:06:02.000Z","date":"2021-04-29","kind":"other","acquired":true,"shares":8,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock."}],"balance_after":7548,"source":{"system":"sec-edgar","filing":"0000905718-21-000630","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000630/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735829,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-04-29T20:05:26.000Z","date":"2021-04-29","kind":"exercise","acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."}],"balance_after":0,"derivative":{"exercise_date":"2016-04-29","underlying":"Common Stock","underlying_shares":325},"source":{"system":"sec-edgar","filing":"0000905718-21-000629","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000629/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735828,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T20:05:26.000Z","date":"2021-04-29","kind":"exercise","acquired":true,"shares":325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00."}],"balance_after":1566,"source":{"system":"sec-edgar","filing":"0000905718-21-000629","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000629/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2735827,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T20:05:26.000Z","date":"2021-04-29","kind":"other","acquired":true,"shares":3,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock."}],"balance_after":1241,"source":{"system":"sec-edgar","filing":"0000905718-21-000629","document":"kintara_fm4apr292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000629/kintara_fm4apr292021.xml","form_type":"4"}},{"id":2766366,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-31T20:14:38.000Z","date":"2021-03-31","kind":"other","acquired":true,"shares":8,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":1238,"source":{"system":"sec-edgar","filing":"0000905718-21-000505","document":"kintara_fm4mar312021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000505/kintara_fm4mar312021.xml","form_type":"4"}},{"id":2766365,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-31T20:11:25.000Z","date":"2021-03-31","kind":"other","acquired":true,"shares":17,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":6062,"source":{"system":"sec-edgar","filing":"0000905718-21-000503","document":"kintara_fm4mar312021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000503/kintara_fm4mar312021.xml","form_type":"4"}},{"id":2766364,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-31T20:08:33.000Z","date":"2021-03-31","kind":"other","acquired":true,"shares":22,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":7540,"source":{"system":"sec-edgar","filing":"0000905718-21-000501","document":"kintara_fm4mar312021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571821000501/kintara_fm4mar312021.xml","form_type":"4"}},{"id":2925631,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-04T13:01:09.000Z","date":"2020-12-31","kind":"other","acquired":true,"shares":17,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":6045,"source":{"system":"sec-edgar","filing":"0000899243-21-000044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321000044/doc4.xml","form_type":"4"}},{"id":2925629,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-04T13:00:37.000Z","date":"2020-12-31","kind":"other","acquired":true,"shares":8,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":1230,"source":{"system":"sec-edgar","filing":"0000899243-21-000043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321000043/doc4.xml","form_type":"4"}},{"id":2925630,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-04T13:00:23.000Z","date":"2020-12-31","kind":"other","acquired":true,"shares":22,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":7518,"source":{"system":"sec-edgar","filing":"0000899243-21-000042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000089924321000042/doc4.xml","form_type":"4"}},{"id":3019856,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T20:06:48.000Z","date":"2020-09-30","kind":"other","acquired":true,"shares":8,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":1222,"source":{"system":"sec-edgar","filing":"0000905718-20-000999","document":"kintara_fm4sep302020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000999/kintara_fm4sep302020.xml","form_type":"4"}},{"id":3019857,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-30T20:06:16.000Z","date":"2020-09-30","kind":"other","acquired":true,"shares":22,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":7496,"source":{"system":"sec-edgar","filing":"0000905718-20-000998","document":"kintara_fm4sep302020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000998/kintara_fm4sep302020.xml","form_type":"4"}},{"id":3019855,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-09-30T20:05:46.000Z","date":"2020-09-30","kind":"other","acquired":true,"shares":17,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":6028,"source":{"system":"sec-edgar","filing":"0000905718-20-000997","document":"kintara_fm4sep302020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000997/kintara_fm4sep302020.xml","form_type":"4"}},{"id":3022949,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientifc Officer"}}],"security":"Options (Right to Buy)","published_at":"2020-09-24T23:31:19.000Z","date":"2020-09-22","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021."}],"balance_after":60000,"derivative":{"exercise_price":1.355,"expiration_date":"2030-09-22","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000905718-20-000984","document":"kintara_fm4sep222020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000984/kintara_fm4sep222020.xml","form_type":"4"}},{"id":3022948,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options (Right to Buy)","published_at":"2020-09-24T23:28:39.000Z","date":"2019-11-12","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This amendment is being filed to update the vesting schedule of the option award made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vested on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021."}],"balance_after":250000,"derivative":{"exercise_price":0.735,"expiration_date":"2029-11-12","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000905718-20-000982","document":"kintara_fm4anov142019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000982/kintara_fm4anov142019.xml","form_type":"4/A","original_submission_date":"2019-11-14"}},{"id":3028430,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:12:10.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":606557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021."}],"balance_after":606557,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":606557},"source":{"system":"sec-edgar","filing":"0000905718-20-000975","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000975/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028422,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":146574,"kind":"person","name":"Liatos John","position":1,"cik":"0001821508","reported_name":"Liatos John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:09:44.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":506647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021."}],"balance_after":506647,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":506647},"source":{"system":"sec-edgar","filing":"0000905718-20-000973","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000973/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028421,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110031,"kind":"person","name":"Brown Dennis M","position":1,"cik":"0001569520","reported_name":"Brown Dennis M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:08:34.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":87437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021."}],"balance_after":87437,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":87437},"source":{"system":"sec-edgar","filing":"0000905718-20-000971","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000971/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028419,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":132665,"kind":"person","name":"Zarrabian Saiid","position":1,"cik":"0001495521","reported_name":"Zarrabian Saiid","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:07:19.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":2715004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021."}],"balance_after":2715004,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":2715004},"source":{"system":"sec-edgar","filing":"0000905718-20-000969","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000969/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028817,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"HOFFMAN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:05:16.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020"}],"balance_after":120000,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000905718-20-000967","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000090571820000967/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028418,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:03:45.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020."}],"balance_after":120000,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000905718-20-000965","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000965/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028420,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":68503,"kind":"person","name":"Murphy Keith","position":1,"cik":"0001536583","reported_name":"Murphy Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:00:48.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020."}],"balance_after":120000,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000905718-20-000963","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000963/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3028417,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110033,"kind":"person","name":"Johnson Laura L.","position":1,"cik":"0001589362","reported_name":"Johnson Laura L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T00:59:17.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020."}],"balance_after":120000,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000905718-20-000961","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000961/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3049891,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":146574,"kind":"person","name":"Liatos John","position":1,"cik":"0001821508","reported_name":"Liatos John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2020-08-21T20:17:19.000Z","date":"2020-08-19","kind":"purchase","acquired":true,"shares":196750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 125,000 shares of Adgero Biopharmaceuticals Holdings, Inc. (\"Adgero\") common stock, par value $0.0001 per share, in connection with the completion of the merger (the \"Merger\"), on August 19, 2020 (the \"Effective Date\"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share."}],"balance_after":196750,"source":{"system":"sec-edgar","filing":"0001213900-20-023272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020023272/ownership.xml","form_type":"4"}},{"id":3049890,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":68503,"kind":"person","name":"Murphy Keith","position":1,"cik":"0001536583","reported_name":"Murphy Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-21T20:16:34.000Z","date":"2020-08-19","kind":"purchase","acquired":true,"shares":181010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 115,000 shares of Adgero Biopharmaceuticals Holdings, Inc. (\"Adgero\") common stock, par value $0.0001 per share, in connection with the completion of the merger (the \"Merger\"), on August 19, 2020 (the \"Effective Date\"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share."}],"balance_after":181010,"source":{"system":"sec-edgar","filing":"0001213900-20-023271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020023271/ownership.xml","form_type":"4"}},{"id":3096579,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2020-06-30T20:17:36.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":57170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 5, 2019, the reporting person received options to purchase 57,170 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months which commenced on April 5, 2020."}],"balance_after":108366,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":57170},"source":{"system":"sec-edgar","filing":"0001213900-20-016319","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016319/ownership.xml","form_type":"4"}},{"id":3096578,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":124937,"kind":"person","name":"Praill Anthony Scott","position":1,"cik":"0001332948","reported_name":"Praill Anthony Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-30T20:17:36.000Z","date":"2020-06-30","kind":"other","acquired":true,"shares":22,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":7474,"source":{"system":"sec-edgar","filing":"0001213900-20-016319","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016319/ownership.xml","form_type":"4"}},{"id":3096577,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":138954,"kind":"person","name":"Bell John K","position":1,"cik":"0001569585","reported_name":"Bell John K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-06-30T20:14:44.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001213900-20-016315","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016315/ownership.xml","form_type":"4"}},{"id":3096576,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":138954,"kind":"person","name":"Bell John K","position":1,"cik":"0001569585","reported_name":"Bell John K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T20:14:44.000Z","date":"2020-06-30","kind":"other","acquired":true,"shares":29,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Onbelay Capital Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":9817,"source":{"system":"sec-edgar","filing":"0001213900-20-016315","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016315/ownership.xml","form_type":"4"}},{"id":3096575,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2020-06-30T20:12:46.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001213900-20-016310","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016310/ownership.xml","form_type":"4"}},{"id":3096574,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":110032,"kind":"person","name":"TOTH ROBERT JOSEPH JR","position":1,"cik":"0001585020","reported_name":"TOTH ROBERT JOSEPH JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T20:12:46.000Z","date":"2020-06-30","kind":"other","acquired":true,"shares":8,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock."}],"balance_after":1214,"source":{"system":"sec-edgar","filing":"0001213900-20-016310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020016310/ownership.xml","form_type":"4"}},{"id":3096805,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":30860,"kind":"person","name":"Hoffman Robert E.","position":1,"cik":"0001166288","reported_name":"HOFFMAN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-06-30T20:11:13.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001213900-20-016308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166288/000121390020016308/ownership.xml","form_type":"4"}},{"id":3096739,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":41363,"kind":"person","name":"Ferrara Napoleone","position":1,"cik":"0001744779","reported_name":"Ferrara Napoleone","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (Right to Buy)","published_at":"2020-06-30T20:09:46.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001213900-20-016306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744779/000121390020016306/ownership.xml","form_type":"4"}}],"next_cursor":"2020-06-30T20:09:46.000000Z,3096739"}